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Fusarochromanone is a powerful anticancer mycotoxin exhibiting unique molecular structure and 
biological activity. Fusarochromanone is produced by rare strains of fusarium equiseti and is not 
readily accessible for study from its natural source; thus, an efficient laboratory synthesis 
practical for large-scale production is an attractive goal. Previously reported syntheses of 
Fusarochromanone are limited by prohibitively expensive starting materials and low-yielding 
key steps. In this work, novel approaches to Fusarochromanone synthesis using directed ortho-
metalation strategies have been proposed and tested. A cost-effective, scalable synthesis of 
Fusarochromanone has been achieved, and groundwork has been laid that will direct future 
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 The synthesis of natural products is a compelling goal for synthetic chemists because 
compounds isolated from nature often have desirable properties, particularly for the treatment of 
disease. Many powerful drugs have been isolated or derived from natural molecules. For this 
reason, naturally-produced biological compounds are common synthetic targets.  
 Fusarochromanone (FC101, 1) is a fungal metabolite produced by the fusarium family of 
fungi. It was first isolated in the 1980s when an outbreak of tibial dyschondroplasia in chickens 
was traced back to fungal growth on feedstocks.1 The isolated compound was then characterized 
by NMR spectroscopy and X-ray crystallography.2 The structure of Fusarochromanone is shown 
in Figure 1.  
Figure 1: Chemical structure of 
Fusarochromanone (FC101) 
 
 Isolated FC101 was shown to cause tibial dyschondroplasia in vitro and in vivo, 
confirming it as the biologically active source of disease in the outbreak.1 Preliminary drug 
studies established FC101 as a structurally unique compound displaying novel modes of action 
in biological systems.3 Further exploration of its biological activity ensued, and in vitro and in 
vivo studies have shown that FC101 exhibits potent cytotoxic activity that is highly selective 
toward many cancer cells over normal cells, which is essential for a favorable drug candidate.3,4,5 
Specifically, it has been shown that FC101 induces apoptotic cell death in glioblastomas and 
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inhibits glioblastoma cell migration, which is especially promising because glioblastomas are 
resistant to current surgical resection, radiation therapy, and chemotherapy treatments.4 FC101 
has also been shown to selectively inhibit growth of melanomas (skin cancer cells), leaving 
normal melanocytes (skin cells) unaffected.5  
However, despite studies that have attempted to elucidate the molecular mechanism of 
FC101 action, the molecular target of FC101 is not yet known.6,7,8 In addition, FC101 is not 
readily available to be extracted from the environment in quantities conducive to study,9 and the 
current synthetic methods reported in the literature are neither cheap nor scalable. Thus, we 
initiated this project with two primary goals: 1. To synthesize Fusarochromanone for biological 
study and 2. To develop and optimize a cheap, efficient and scalable total synthesis of 
Fusarochromanone for kilogram-scale production. Such a method will be crucial to the success 
of further investigation of the molecular target of FC101 and, ultimately, determination of the 
efficacy of FC101 and analogues as a cancer treatment. 
The two previously reported syntheses of Fusarochromanone start with 
aminochromanone 2. The first synthesis (Scheme 1), patented in 2004, uses a Pd-catalyzed 
Negishi coupling as the key step to install the aminoalcohol sidechain onto the 
aminochromanone (2) scaffold. The major limitation of this method is the low yield: the 
iodination of 2 proceeded in only 30% yield and the following cross-coupled product 5 was 
afforded in only 11% yield. The final deprotection step did not result in any usable product, but 





Scheme 1: Patented10 synthesis of Fusarochromanone 
 
 The second synthesis of Fusarochromanone in the literature was reported by Tanaka et al. 
in 2016.11 The authors reported a concise synthetic route (Scheme 2) that uses a Rh-catalyzed 
oxidative olefination followed by a Pd-catalyzed Wacker oxidation to attach and oxidize the 
aminoalcohol sidechain to the aminochromanone scaffold. This method affords 
Fusarochromanone in good overall yield with efficient step-economy, but is limited by its 
prohibitively expensive starting materials: Both the aminochromanone 2 and the precursor to the 
chiral oxazolidinone 7 are sold commercially in excess of $300 per gram. Rhodium and 
palladium are also very expensive, making alternative methods of attaching and modifying the 
aminoalcohol sidechain desirable. As reported, the Tanaka et al. method is not financially 
practical, especially for the goal of kilogram-scale production. A novel strategy is needed.  
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Scheme 2: Synthesis of Fusarochromanone reported by Tanaka et al.11 
 
 Although a seemingly simple molecule at first glance, previous synthetic efforts highlight 
a few significant difficulties presented by the structure of FC101. The substitution pattern on the 
aromatic ring is difficult to achieve using classical methods like electrophilic aromatic 
substitution (EAS) because of regioselectivity problems. Nitration of the chromanone scaffold is 
regioselective for the position meta to the ketone substituent rather than the desired ortho 
position, as shown in Scheme 3.12 
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Scheme 3: Regioselectivity barrier to electrophilic aromatic  
substitution (EAS) of Aminochromanone 2 (Adapted from ref. 12). 
  
 To circumvent the EAS regioselectivity challenges presented by the tetrasubstituted 
aminochromanone scaffold, we devised the strategy shown by retrosynthetic analysis in Figure 2. 
The key steps in our proposed synthesis rely on directed ortho-metalation (DoM) at both 
positions ortho to the amine substituent of 3-aminophenol (16). Directed ortho-metalation is a 
reaction paradigm that was introduced concurrently by Gilman and Wittig around 1940.13,14 
DoM takes advantage of coordination between strong organometallic bases and heteroatomic 
aromatic substituents, termed Directing Metalation Groups (DMGs), to regioselectively 
deprotonate aromatic hydrocarbons (metalation denotes the replacement of a hydrogen atom by a 
metal atom). In DoM, the metalated intermediate is strongly nucleophilic and thus can readily 
couple with electrophiles at metalated positions. A general DoM reaction is presented in Scheme 
4.  
Scheme 4: A general DoM reaction: ortho-lithiation of a DMG-substituted  
aromatic by a butyllithium reagent (RLi) and subsequent incorporation  




Figure 2: Retrosynthetic analysis of Fusarochromanone:  
Our initial double-DoM strategy 
 
Butyllithium reagents are the most commonly used bases for DoM because they: 1. 
exhibit powerful enough basicity to deprotonate aromatic unsaturated hydrocarbons and 2. 
contain a Lewis acidic metal atom (Li) that can coordinate with Lewis basic DMGs to facilitate 
regioselective metalation.15,16,17 Solvated butyllithium reagents exist as aggregate structures of 
varying geometries depending on solvent interactions. For example, in hydrocarbon solvents 
such as toluene, butyllithiums tend to react as hexamers, while in basic solvents like 
tetrahydrofuran (THF) and diethyl ether (Et2O), butyllithiums tend to react as dissociated dimers 
and monomers. In addition, rate studies have shown that kinetic basicity increases as aggregate 
size decreases. Thus, THF and Et2O are advantageous solvents from a kinetic perspective. 
Additionally, bidentate ligands, particularly tetramethylethylenediamine (TMEDA), effectively 
break apart alkyllithium aggregates, significantly increasing rates of lithiation in many cases.15,16 
 However, the nature of the DMG(s) involved may have the most significant influence on 
the rates of DoM reactions, and DMG selection is important in any synthesis using DoM. 
Quantitative data comparing lithiation rates by varying DMG are lacking in the literature, but 
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qualitative hierarchies have been established that provide reasonable guides for DMG selection 
in synthetic applications. One reviewer points out that in metalation chemistry, “a systematic 
search for the optimum conditions by variation of alkyllithiums, solvents, and complexing agents 
invariably proves to be rewarding.”15 
Generally, DMGs must contain a good coordinating site for alkyllithiums, usually a 
heteroatom. DMGs must also be poor electrophilic sites to avoid nucleophilic attack by 
alkyllithium reagents. Other considerations include steric hindrance, which can affect the 
approach of the alkyllithium base, and charge activation/deactivation and induction, which can 
affect the acidity of the protons at desired lithiation positions.15,16 
With these considerations in mind, we chose protecting groups for the amine and alcohol 
substituents of 16 based on qualitative DMG strengths reported in the literature. Since the amine 
is meta to the alcohol in 16, the phenomenon of cooperative metalation effects, in which 1,3-
related DMGs promote ortho-lithiation at their common site, was of particular interest to us. 
Pivaloyl-protected amines and ether-protected alcohols have been shown to act as strong 
cooperative DMGs.15,16 For these reasons, we selected pivaloyl (Piv) and tetrahydropyranyl 
(THP) protecting groups for our initial studies.  
The chief advantages of the described double DoM strategy for synthesis of FC101 are 
step economy and cost-effectiveness. The proposed synthesis would take no more than ten steps 
starting from 3-aminophenol (16), which is commercially available at $0.20 per gram. The key 
steps employ relatively cheap butyllithium reagents, which stands in contrast to the use of 
expensive transition metal catalysts in previous syntheses.10,11 
 In this work, the synthetic route presented in Figure 2 was tested with the aforementioned 
goals of synthesizing Fusarochromanone in a practical way for biological study and optimizing a 
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synthetic route for kilogram-scale production of Fusarochromanone. Optimization studies 
involving a tertbutyloxycarbonyl (Boc) protected amine were attempted, as well as an alternative 
site-selective DoM strategy using a bulky triisopropylsilyl (TIPS)-protected alcohol. 
Results: 
 
Bis-protection of 3-aminophenol (16): 
 
Starting with the cheap, commercially available material 3-aminophenol (16), we 
attempted the synthesis shown in our retrosynthetic analysis (Figure 2). The protection steps 
proceeded smoothly in excellent yields without purification (Scheme 5). Piv-protection of the 
meta-amine substituent of 16 worked in 96% yield. The crude, product 20 was carried forward 
and the subsequent THP protection of the alcohol proceeded in 94% yield. The crude product 22 
was then carried forward for the first round of ortho-lithiation testing. 
Scheme 5: Consecutive Piv and THP protections of 3-aminophenol (16) 
 
Lithiation of bis-protected aminophenol 22: 
 
Initial attempts to lithiate 22 returned disappointing results. Based on the conditions of 
previously reported lithiation reactions18, we added n-butyllithium (n-BuLi) at -78 °C, waited 10 
minutes to allow ortho-lithiation, then added crotonaldehyde (23) as a model electrophile. After 
20 minutes, no reaction progress was indicated by TLC. Analysis of the crude reaction mixture 
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by NMR showed only starting material (22), confirming lithiation failure. NMR spectra of 
subsequent attempts using a fresh bottle of n-BuLi, a fresh tank of dry N2, and quenching with 
deuterated methanol (MeOD) returned identical results. Deuterated methanol was chosen as the 
electrophile to simplify analysis: lithiation success could be judged by disappearance or 
reduction in the integration of the proton peak corresponding to the cooperative metalation site.   
It soon became apparent that temperature was a decisive variable. When n-BuLi was 
added to 22 in THF at 0 °C (Scheme 6), the clear solution turned yellow. No color change had 
been observed previously. When the mixture was treated with 3-methyl-2-butenal (23) at -78 °C 
and allowed to warm up to room temperature, TLC indicated significant conversion of 22. 1H 
NMR analysis showed a diastereomeric mixture of the desired ortho-substituted product (24). 
Crude alcohol 24 was purified via column chromatography before being carried forward to 
attempt the second lithiation at the remaining “open” position ortho to the PivNH DMG. Some of 
this material was treated with tertbutyldimethylsilyl triflate (TBSOtf) in dichloromethane (DCM) 
to protect the alcohol with a tertbutyldimethylsilyl (TBS) group (26, Table 1). 






Attempted lithiation of bis-protected diastereomeric alcohol 24 
 
Attempts to lithiate 24 and 26 ortho to PivNH, the position where the FC101amino-
alcohol sidechain needs to be installed, were unsuccessful. Attempted variations in reagents and 
conditions are shown in Table 1. In our first attempt to install an electrophile at the sidechain 
position of 24, ortho to the protected amine, we used the procedure and conditions reported in 
Scheme 6 that had been successful in the first lithiation (entry 1 in Table 1), but unfortunately 
these proved unsuccessful. A number of modifications were attempted, including the previously-
mentioned TBS protection of the alcohol substituent (26), using stronger lithiating reagents like 
sec-butyllithium (s-BuLi) and s-BuLi/TMEDA, varying the temperature, and changing the 
solvent from THF to Et2O, which tolerates butyllithium reagents better.19,20 These did not 
improve outcomes. 1H NMR analyses of all attempted deuterations (entries 1-5) showed starting 
material with the exception of entry 5, which showed a 50% reduction in integration of the peak 
at 7.72 ppm corresponding to the ortho site (Figure A11). A follow-up GCMS study of the crude 
reaction mixture seemed to confirm successful deuteration (Figure A12). Unfortunately, 
subsequent efforts to trap the lithiated material with 4-chlorobenzaldehyde (entries 6-9) failed 









Table 1: Attempts to ortho-lithiate 24 and 26 at various  











time (min) Solvent Electrophile (E) 
1 24 n-BuLi 0 40 THF MeOD 
2 24 s-BuLi 0 40 THF MeOD 
3 24 s-BuLi/TMEDA 0 60 THF MeOD 
4 24 s-BuLi/TMEDA -78 10 THF MeOD 
5 26 s-BuLi/TMEDA -78 12 Et2O MeOD 
6 26 s-BuLi/TMEDA -78 75 Et2O 4-chlorobenzaldehyde 
7 26 s-BuLi/TMEDA -78 60 Et2O 4-chlorobenzaldehyde 
8 26 s-BuLi/TMEDA -40 30 Et2O 4-chlorobenzaldehyde 
9 26 s-BuLi/TMEDA -40 75 Et2O 4-chlorobenzaldehyde 
 
Synthesis of N-pivaloyl aminochromanone 29 and elaboration to 
fusarochromanone: 
 
 At this point, we determined that our strategy of ortho-lithiating 24 to install the 
aminoalcohol sidechain was not feasible. However, we realized that aminochromanone starting 
material 2, used in the Tanaka synthesis,11 could be accessed from 24 by successive alcohol 
oxidization and ring-closing reactions (Scheme 7). This would provide us with a cost-effective 




Scheme 7: Cost-effective synthesis of 29, a Piv-protected  
variant of aminochromanone 2 
 
Oxidation of alcohol 24 required a large excess of manganese dioxide (MnO2), but 
worked smoothly in 91% yield and the ketone product 28 was carried forward without 
purification. Removal of the THP protecting group using p-toluenesulfonic acid (PTSOH) in 
methanol and the subsequent ring closing in sodium hydroxide (NaOH) were achieved in 75% 
yield back-to-back in the same flask, yielding N-pivaloylaminochromanone 29. The pivaloyl 
group can be removed by heating in concentrated acid to give 2 if desired. In Tanaka et al., 2 was 
protected with an acetyl (Ac) group to give N-acetylaminochromanone 6. However, switching 
out the pivaloyl group for an acetyl group would add several steps to our synthesis. We predicted 
that using our N-pivaloyl derivative would not significantly affect the outcome of the oxidative 
olefination, so 29 was carried forward by Dr. Nicholas Dodge to attempt the synthesis of 
Fusarochromanone based on the route devised by Tanaka et al. in 2016 (Scheme 8).  
 The route to Fusarochromanone was completed using N-pivaloylaminochromanone 29 
and chiral oxazolidinone 7 (synthesized from a literature procedure21 by Dr. Nicholas Dodge). 
The Rh-catalyzed coupling to form 30 and subsequent Pd-catalyzed Wacker oxidation to form 31 
proceeded in moderate to good yields without incident. However, the final deprotection step, 
removal of the pivaloyl protecting group, required harsh conditions (concentrated acid and high 
temperatures) and afforded Fusarochromanone in only 30% (step yield), even after several 
optimization attempts.12  
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Scheme 8: Elaboration of 29 to Fusarochromanone based on Tanaka synthesis 
 
Attempted lithiation of N-Boc aminophenol 32: 
 
Having successfully synthesized our target relying partially on the previous route 
reported by Tanaka et al., we set out to both optimize our method and explore alternative ways to 
apply DoM to develop a new total synthesis of Fusarochromanone. Toward the former, we 
needed to remedy the low-yielding deprotection of the amine at the end of our synthetic route. 
We decided to use the Boc protecting group, which is known to come off under much milder 
conditions than Piv (dilute acid and ambient temperatures).22 However, BocNH substituents are 
weaker DMGs than PivNH substituents and require the very reactive lithiating reagent t-BuLi to 
achieve ortho-lithiated products.15,16,22 Stanetty and coworkers reported that ortho-lithiation of N-
Boc-anilines worked optimally when left for 3 hours in a -10 °C diethyl ether solution.19 
However, when those conditions were applied to our substrate (32), no ortho-installation of 
electrophile was observed. Deuterated methanol was again used to test for lithiation success. In 
addition, model electrophiles 4-chlorobenzaldehyde and crotonaldehyde were used because the 
reactive functional group of a substrate used to form the Fusarochromanone aminoalcohol 
sidechain would be an aldehyde. 1H NMR analyses of entries 1 and 2 in Table 2 showed no 
reduction in the ortho proton peaks, indicating that no ortho-deuteration occurred. Likewise, 
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NMR analyses of entries 3-5 in Table 2 showed only starting materials, indicating that the model 
aldehyde electrophiles were not incorporated as desired.  
Table 2: Attempts to ortho-lithiate Boc- and THP- protected  
3-aminophenol (16) at various temperatures to  










1 t-BuLi -20 15 MeOD 
2 t-BuLi -20 180 MeOD 
3 t-BuLi -20 180 4-chlorobenzaldehyde 
4 t-BuLi -20 180 4-chlorobenzaldehyde 
5 t-BuLi -10 180 crotonaldehyde 
 
Attempted lithiation of O-TIPS aminophenols 34 and 36: 
 
The most promising lead toward a new DoM strategy emerged from a report that bulky 
TIPS-protected oxygen substituents suppress ortho-lithiation.23 Theoretically, then, an OTIPS-
substituted substrate would cause the nitrogen-based DMG to direct selectively to the position 
where the aminoalcohol sidechain would need to be installed (see scheme, Table 3). This would 
allow incorporation of the sidechain moiety before formation of the ether-containing six-
membered ring. 
Unfortunately, DoM studies thus far have been mostly unsuccessful. Given the 
difficulties with ortho-lithiation of 32 shown in Table 2, DoM of both 34 (Table 3) and 36 (Table 
4) were attempted. NMR analyses of deuteration attempts (entries 1-3 in Table 3 and entries 1-3 
in Table 4) all showed zero reduction in ortho proton peaks except for entry 3 in Table 3. When 
lithiation with t-BuLi was attempted at 0 °C for 3 hours, followed by a deuterated methanol 
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quench, 1H NMR analysis showed a mixture of ortho-deuterated product and starting material 34 
(Figure A13). Unfortunately, this spectrum was misinterpreted initially, and lithiation under the 
conditions listed in entry 3 of Table 3 were never attempted using a model aldehyde electrophile. 
1H NMR spectra of attempts to incorporate aldehyde electrophiles under other conditions (entries 
4-6 in Table 3 and entry 4 in Table 4) showed only starting materials.  
Table 3: Attempts to ortho-lithiate Boc- and TIPS- protected  
3-aminophenol (16) at various temperatures to  










1 t-BuLi -20 120 MeOD 
2 t-BuLi -10 180 MeOD 
3 t-BuLi 0 180 MeOD 
4 t-BuLi -20 180 4-chlorobenzaldehyde 
5 t-BuLi -10 240 4-chlorobenzaldehyde 
6 t-BuLi -10 180 Crotonaldehyde 
 
Table 4: Attempts to ortho-lithiate Piv- and TIPS- protected  
3-aminophenol (16) at various temperatures to  









1 t-BuLi 0 180 MeOD 
2 n-BuLi 0 45 MeOD 
3 t-BuLi 0 150 MeOD 
4 t-BuLi -10 180 crotonaldehyde 
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Discussion and Future Work: 
 
The work presented here and by Dr. Nicholas Dodge12 establishes a scalable, cost-effective 
synthesis of aminochromanone 2 using directed ortho-metalation. Additional work by Dr. 
Nicholas Dodge demonstrates the elaboration of 2 to the natural product according to work 
presented by Tanaka et al.12 This is a 10-step route that requires only one round of 
chromatography starting from 3-aminophenol (16), which is both cheap ($0.20/gram) and 
commercially available. Thus, one of the two stated goals of this work has been achieved. That 
is, an efficient, practical synthesis of the anticancer fungal metabolite Fusarochromanone is now 
available. 
However, much optimization work remains. The conditions required for the final pivaloyl-
deprotection step cause significant product decomposition (31 to 1, Scheme 8), and the ortho-
lithiation attempts presented here using the more labile Boc group have been unsuccessful (Table 
2).  
Additionally, even after considering our cheap synthesis of 2, the Tanaka et al. route is still 
relatively expensive due to its Rh-catalyzed oxidative olefination and Pd-catalyzed Wacker 
oxidation steps (Scheme 29 to 31, Scheme 8). Our double DoM strategy (Figure 2) was 
unsuccessful due to difficulties with ortho-lithiation of tri-substituted 24 and 26 (Table 1). Our 
alternative DoM strategy, to install the amino-alcohol sidechain substituent first (before 
incorporating the six-membered ring) by blocking the cooperative lithiation site with a bulky O-
TIPS group, proved mostly unsuccessful as well (Tables 3 and 4). However, when lithiation was 
attempted at a higher temperature (0 °C, entry 3, Table 3) and quenched with deuterated 
methanol, a mixture of starting material and ortho-deuterated product was observed (Figure 
A13). Lithiating under these conditions and quenching with model aldehydes was not attempted. 
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Future investigations into site-selective lithiation of O-TIPS-substituted aminophenols should 
therefore begin here. 
Several factors must be considered when trying to rationalize the observed failure of 
lithiation attempts. Speaking broadly, there are two possibilities: first, the lithiation 
(regioselective deprotonation of the aromatic ring) is working, but something is preventing 
reaction of the lithiated species with electrophile. For example, steric hindrance of aromatic 
substituents could prevent the approach of the electrophile. However, this seems unlikely given 
the literature consensus that lithiation is the rate-limiting step in DoM reactions, not electrophilic 
attack.15,16 If lithiation were occurring, even partially, we would expect to see evidence of at least 
some incorporation of electrophile. The second possibility is that the lithiation itself is failing, 
which would obviously prevent any incorporation of electrophile. The results presented in this 
work strongly support this conclusion because attempts to incorporate deuterium, which is not 
sterically hindered and should substitute at lithiated sites rapidly, produced NMR spectra with 
aromatic proton integrations identical to those of corresponding starting materials, indicating 
negligible, if any, deuteration. As previously stated, the only exception was the result presented 
in entry 3 of Table 3, which indicates that at higher temperatures lithiation of O-TIPS-substituted 
aminophenols may prove viable.  
The majority of future work should focus on the problem of total synthesis. Despite the 
unsuccessful results reported thus far, DoM strategies remain attractive options for overcoming 
the difficulties with contiguous tetra-substitution of the aromatic ring in 1. DoM reactions are 
particularly fickle, and this work did not rigorously vary all of the factors that could affect the 
outcome of metalations. Notably, the reported reactions were not tested according to substrate 
concentration, which is known to be an important parameter in DoM reactions. Instead, 
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temperature was varied most extensively because the successful lithiation of 22 (Scheme 6) at 0 
°C was achieved only after many failed attempts at lower temperatures. This strategy of 
screening conditions in a trial-and-error fashion was adopted for the work that followed. Now 
that many sets of conditions have been tested, it seems clear that more rigorous studies of 
pertinent DoM reactions are necessary to try to understand exactly why DoM is failing. This may 
involve real-time reaction monitoring and more meticulous characterization of side products to 
determine what is going on kinetically. Many other variables remain to be tested before 



















General Experimental Details: 
 
 All reactions were performed in glassware with magnetic stirring in a fume hood. Air-
sensitive lithiation reactions were carried out in flame-dried glassware under a nitrogen 
atmosphere. Plastic syringes were used to dispense liquid and solubilized reagents. Solvents were 
removed under vacuum using a rotary evaporator attached to a dry vacuum pump. 
Tetrahydrofuran (THF) and diethyl ether (Et2O) were dried via a solvent dispensing 
system. Tertbutyldimethylsilyl trifluoromethanesulfonate (TBSOTf) was purified by vacuum 
distillation before use. Tetramethylethylenediamine (TMEDA) was freshly distilled from 
calcium hydride (CaH2) under a nitrogen atmosphere before use. Butyllithium reagents were 
titrated according to the procedure reported by Chong et al.24 All other commercially available 
reagents were used without further purification or titration. 
Flash column chromatography was performed with manual glassware and on a 
CombiFlash® Rf 150 system using RediSep® Rf Gold silica columns. TLC analysis was 
performed using silica gel on glass plates and visualizing under ultraviolet (UV) light. 
1H NMR data was collected at room temperature on a 500 MHz Bruker spectrometer in 
CDCl3. 1H NMR chemical shifts are reported in ppm (δ units) downfield from tetramethylsilane 
(TMS). Exact mass analysis was performed on a Varian Saturn 2100T ion trap gas 
chromatograph-mass spectrometer operated in chemical ionization (CI) mode with a Varian 3900 
GC and CP-8400 autosampler. 
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Aminophenol Functional Group Protections: 
Compound 20:  
 
Sodium bicarbonate (NaHCO3, 11.76 g) and 3-aminophenol (16) (5.09 g) were dissolved in a 
solution of ethyl acetate (EtOAc, 155 mL) and DI water (200 mL). Pivaloyl chloride (6.0 mL) 
was added and the solution was stirred at room temperature for 30 minutes. The organic phase 
was separated, washed with 2 M HCl, DI water, and brine, then dried over sodium sulfate 
(Na2SO4) and concentrated to give the known18 amide 20 in 96% yield. 1H NMR (500 MHz, 




Di-tert-butyldicarbonate (Boc2O, 12.29 g) and 3-aminophenol (5.12 g) were dissolved in 
tetrahydrofuran (THF, 200 mL). The solution was refluxed for 3 h and left to cool overnight. The 
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reaction solution was concentrated under reduced pressure to give the known25 carbamic acid 
32a.   
Compound 22: 
 
Compound 20 (8.4 g) was dissolved in dichloromethane (DCM, 60 mL). Pyridinium p-
toluenesulfonate (PPTS, 0.24 g) was added and the system was placed under a nitrogen 
atmosphere. Dihydropyran (DHP, 26.0 mL) was added and the solution was stirred for 18 h. The 
organics were washed with 1 M NaOH, dried over Na2SO4, and concentrated under reduced 
pressure to provide the title compound in 94% yield. 1H NMR analysis indicated that this 
material was sufficiently pure to carry on. 1H NMR (500 MHz, CDCl3, δ in ppm): 7.34 (t, 1H), 
7.27 (s, 1H), 7.21 (t, 1H), 7.12 (d, 1H), 6.80 (d, 1H), 5.44 (t, 1H), 3.90 (t, 1H), 3.61 (m, 1H), 2.00 




Compound 32a (9.8 g) was dissolved in dichloromethane (DCM, 61 mL) and pyridinium p-
toluenesulfonate (PPTS, 0.24 g) was added. The reaction was placed under a nitrogen 
atmosphere and dihydropyran (DHP, 25.7 mL) was added. The solution was clear and colorless. 
The reaction was left to stir over the weekend, after which the solution was transparent 
green/brown. The organics were washed with 0.67 M aq. NaOH and brine, then dried over 
MgSO4 and concentrated under reduced pressure. 1H NMR analysis indicated that this material 
was sufficiently pure to carry on. 1H NMR (500 MHz, CDCl3, δ in ppm): 7.17 (s, 1H), 7.16 (t, 
1H), 6.92 (d, 1H), 6.73 (d, 1H), 6.45 (s, 1H), 5.42 (t, 1H), 3.89 (t, 1H), 3.60 (m, 1H), 1.99 (m, 
1H), 1.83 (m, 2H), 1.67 (m, 3H), 1.51 (s, 9H). 
Compound 34: 
 
Compound 32a (2.97 g) and imidazole (1.16 g) were dissolved in dichloromethane (DCM, 36 
mL). Triisopropylsilyl chloride (TIPSCl, 3.29 g) was added and a precipitate was immediately 
observed. The reaction was left to stir overnight. The crude product mixture was diluted in DCM 
and washed with brine. The organics were dried over MgSO4 and concentrated under reduced 
pressure. 1H NMR (500 MHz, CDCl3, δ in ppm): 7.10 (t, 1H), 6.97 (d, 1H), 6.88 (t, 1H), 6.55 (d, 






Compound 20 (3.48 g) and imidazole (1.47 g) were dissolved in dichloromethane (DCM, 45 mL) 
under a nitrogen atmosphere, forming a clear, yellow solution. Tertbutylsilyl chloride (TIPSCl, 
4.62 mL) was added and the solution turned pink then darkened to purple and settled at a dark 
gray. The reaction was left to stir for 17 h. The crude mixture was diluted with DCM and the 
organics were washed twice with brine, dried over MgSO4, and concentrated under reduced 
pressure. The product was a white solid. 1H NMR (500 MHz, CDCl3, δ in ppm): 7.22 (t, 2H), 




Compound 22 (2.0 g) was added to a flame-dried flask and left under high-vacuum for 45 
minutes. The system was transferred from an evacuated atmosphere to a nitrogen atmosphere and 
 24 
dry tetrahydrofuran (THF, 75.0 mL) was added. The mixture was stirred until a clear solution 
was observed, then cooled to 0 °C in an ice bath, at which point 2.06 M n-butyllithium (n-BuLi, 
7.5 mL) was added dropwise. The solution turned yellow after 3.7 mL  n-BuLi (~1 eq.) was 
added. After 45 minutes, the reaction was cooled to -78 °C in a dry ice bath/acetone bath and 3-
methyl-2-butenal (0.86 mL) was added dropwise, causing the solution to become colorless again. 
After 24 h of stirring, the reaction was deep red. The reaction was quenched with 3 pipette-fulls 
of saturated ammonium chloride (NH4Cl) solution, then extracted with diethyl ether (Et2O) 3 
times. The combined organics were washed once with water and twice with brine, then dried 
over MgSO4 and concentrated under reduced pressure. Purified on a silica column using a 10% 
ethyl acetate (EtOAc)/hexanes eluent. 1H NMR (500 MHz, CDCl3, δ in ppm): 9.70 (s, 1H), 7.95 
(d, 1H), 7.18 (t, 1H), 6.82 (d, 1H), 6.32 (d, 1H), 5.59 (d, 1H), 5.34 (t, 1H), 3.90 (t, 1H), 3.61 (m, 




Compound 24 (0.112 g) was dissolved in dichloromethane (DCM, 5.0 mL) under a nitrogen 
atmosphere, and 2,6-lutidine (0.05 mL) was added. The reaction was cooled to 0 °C in an ice 
bath, tertbutyldimethylsilyl triflate (TBSOTF, 0.10 mL) was added, and the reaction was stirred 
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for 16 h. The brown/orange reaction mixture was then diluted in DCM. The organics were 
washed with sodium bicarbonate (NaHCO3) once, water 4 times, and brine once, then dried over 
MgSO4 and concentrated under reduced pressure. The crude product was purified on a silica 
column using a 10% EtOAc/hexanes eluent. The pure product was isolated in 73% yield. 1H 
NMR (500 MHz, CDCl3, δ in ppm): 9.61 (s, 1H), 7.86 (d, 1H), 7.14, (t, 1H), 6.86 (d, 1H), 6.24 
(d, 1H), 5.60 (d, 1H), 5.39 (t, 1H), 3.90 (t, 1H), 3.63 (t, 1H), 2.00 (m, 1H), 1.88 (m, 1H), 1.85 (m, 
1H), 1.71 (s, 3H), 1.70 (m, 2H), 1.64 (s, 3H), 1.59 (m, 1H), 1.33 (s, 9H), 0.87 (s, 9H), 0.17 (s, 
3H), 0.09 (s, 3H). 
Completion of aminochromanone: 
Compound 28 
 
Compound 24 (0.36 g) and manganese dioxide (MnO2, 3.65 g) were combined in a flask and dry 
dichloromethane (DCM, 15 mL) was added under a nitrogen atmosphere. The reaction was left 
to stir overnight. The reaction mixture was filtered over a celite plug to remove MnO2 and 
concentrated under reduced pressure. 1H NMR (500 MHz, CDCl3, δ in ppm): 10.04 (s, 1H), 8.03 
(d, 1H), 7.31 (t, 1H), 6.90 (d, 1H), 6.54 (s, 1H), 5.46 (t, 1H), 3.83 (t, 1H), 3.63 (d, 1H), 2.21 (s, 




Compound 28 (1.05 g) and p-toluenesulfonic acid (PTSOH, 0.10 g) were dissolved in methanol 
(MeOH, 35 mL) and left to stir overnight. The crude product was extracted in diethyl ether 
(Et2O) 3 times. The combined organics were washed with water 3 times, dried over MgSO4, and 
concentrated under reduced pressure.  
Compound 29: 
 
Compound 28a (1.0 g) was dissolved in 0.4 M aq. Sodium hydroxide (NaOH) solution (150 mL) 
and stirred for 1.5 h. The product was a white precipitate that crashed out of the aqueous reaction 
solution as it formed. The product was collected by vacuum filtration. 1H NMR (500 MHz, 
CDCl3, δ in ppm): 11.99 (s, 1H), 8.31 (d, 1H), 7.42 (t, 1H), 6.59 (d, 1H), 2.75 (s, 2H), 1.46 (s, 




Compound 29 (0.111 g) was dissolved in concentrated hydrochloric acid (conc. HCl, 0.9 mL) in 
a vial. Dioxane (1 mL) was added as a cosolvent. The reaction was heated to 70 °C in an oil bath. 
The reaction was left to stir overnight. The reaction was quenched with saturated sodium 
bicarbonate (NaHCO3) solution. The crude product was extracted into ethyl acetate (EtOAc) 3 
times. The organics were dried over MgSO4 and concentrated under reduced pressure. 1H NMR 
(500 MHz, CDCl3, δ in ppm): 7.13 (t, 1H), 6.30 (s, 2H), 6.14 (d, 1H), 6.12 (d, 1H), 2.67 (s, 2H), 
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1H NMR (500 MHz, CDCl3) δ  7.57, 7.31, 7.26, 7.18, 7.16, 7.15, 6.76, 6.74, 6.62, 6.61, 1.32.
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1H NMR (500 MHz, CDCl3) δ 5.45, 5.44, 5.43, 3.92, 3.90, 3.88, 3.63, 3.62, 3.61, 3.60, 3.59, 2.04,
















































































































































































































































1H NMR (500 MHz, CDCl3) δ  9.70, 7.96, 7.94, 7.19, 7.18, 7.16, 6.91, 6.89, 6.83, 6.81, 6.33, 6.31,
6.29, 6.28, 5.63, 5.60, 5.58, 5.37, 5.34, 3.92, 3.90, 3.88, 3.83, 3.81, 3.79, 3.63, 3.62, 3.61, 3.59, 3.59,
3.57, 2.03, 2.02, 2.01, 2.00, 1.99, 1.98, 1.97, 1.96, 1.90, 1.88, 1.86, 1.83, 1.82, 1.80, 1.71, 1.70, 1.68,
1.67, 1.66, 1.65, 1.64, 1.63, 1.62, 1.32.
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1H NMR (500 MHz, CDCl3) δ  9.61, 9.52, 7.89, 7.87, 7.85, 7.15, 7.14, 7.12, 6.92, 6.90, 6.87, 6.85,
6.25, 6.23, 6.21, 5.63, 5.61, 5.59, 5.39, 5.35, 3.92, 3.90, 3.88, 3.84, 3.82, 3.64, 3.62, 3.59, 2.05, 2.03,
2.01, 2.00, 1.98, 1.96, 1.91, 1.89, 1.87, 1.86, 1.84, 1.83, 1.78, 1.75, 1.74, 1.73, 1.71, 1.69, 1.68, 1.65,
1.64, 1.61, 1.59, 1.57, 1.33, 0.87, 0.84, 0.17, 0.11, 0.09, 0.03.
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1H NMR (500 MHz, CDCl3) δ 7.18, 7.17, 7.16, 7.15, 6.93, 6.92, 6.74, 6.73, 6.45, 5.42, 3.92, 3.89, 3.87,
3.62, 3.61, 3.59, 3.58, 2.03, 1.99, 1.98, 1.95, 1.85, 1.84, 1.83, 1.82, 1.71, 1.69, 1.67, 1.65, 1.63, 1.51.
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1H NMR (500 MHz, CDCl3) δ 10.04, 8.04, 8.02, 7.32, 7.31, 7.29, 6.91, 6.90, 6.54, 5.46, 3.85, 3.83,




























































































































































































































































1H NMR (500 MHz, CDCl3) δ  7.12, 7.10, 7.09, 6.98, 6.97, 6.88, 6.56, 6.54, 6.37, 1.51, 1.30, 1.28,






















































































































































































































































































1H NMR (500 MHz, CDCl3) δ 7.74, 7.72, 7.70, 7.08, 7.06, 7.05, 6.84, 6.83, 6.80, 6.78, 6.17, 6.15,
5.52, 5.51, 5.49, 5.32, 3.84, 3.82, 3.80, 3.57, 3.55, 3.41, 3.38, 1.92, 1.77, 1.24, 0.79, 0.09, 0.01.
27
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Figure A12: CI GCMS spectra showing mixture of 26 and  
















































































































1 1H NMR (500 MHz, CDCl3) δ  7.11, 7.10, 7.09, 7.08, 6.98, 6.96, 6.87, 6.86, 6.55, 6.53, 1.50, 1.28, 1.26,
1.25, 1.23, 1.22, 1.20, 1.10, 1.08.
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